The first human is inside.
That means the world’s first anti-aging gene therapy trial has actually begun.
No simulations. No mouse models this time.
A patient has received the treatment.
It targets retinal cells specifically.
The logic here is deceptively simple.
Scientists want to convince old eye cells to act like young ones again.
If that happens?
Sight might improve.
That is the immediate goal.
But everyone knows it isn’t just about vision.
It is a wedge.
A very small, precise wedge to pry open the door on cellular rejuvenation.
“If it proves to be safe… it could open the door.”
Paul Knoepfler says exactly that.
The cell biology professor at UC Davis knows what is at stake.
Ian Sample of course knows it too.
He is the science editor watching from the sidelines.
Both agree on one thing.
This trial is a proof of concept for something much bigger.
Something potentially messy.
Reversing age.
Really?
Or just repairing specific tissues?
We have to wait for the safety data.
Until then.
We watch the eyes.
And hope they stay open long enough to see what comes next.
